PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling ...

NEW YORK, May 14, 2013 /PRNewswire via COMTEX/ –

Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaSphere: Early-Stage Technology Transfer Collaborations – Enabling Platform Technologies Deal Synergies between Academia and the Pharmaceutical Industryhttp://www.reportlinker.com/p01171136/PharmaSphere-Early-Stage-Technology-Transfer-Collaborations—Enabling-Platform-Technologies–Deal-Synergies-between-Academia-and-the-Pharmaceutical-Industry.html#utm_source=prnewswireutm_medium=prutm_campaign=Drug_and_Medication

PharmaSphere: Early-Stage Technology Transfer Collaborations – Enabling Platform Technologies Deal Synergies between Academia and the Pharmaceutical Industry

Summary

“PharmaSphere: Early-Stage Technology Transfer Collaborations – Enabling Platform Technologies Deal Synergies between Academia and the Pharmaceutical Industry” report provides a cross-section of major licensing deals between mid to large-sized pharmaceutical companies and academic and nonprofit research institutions. This report examines the terms, platform technologies, and deal rationale of 25 pharma-academic alliances from 2012-2013. GlobalData’s Industry Dynamics team of analysts discusses the significant macro-environment drivers which are leading to an increase in research partnerships with academic research institutions on behalf of pharmaceutical companies. We also discuss the unsustainability of the current drug research model, and the industry’s attempts at moving toward an open RD ecosystem.

Highlights

Key Questions Answered

What are the reasons for increased activity in strategic deals with academia by leading pharmaceutical companies and promising biotechs?- What are the deal terms of these collaboration agreements?- What therapeutic areas and geographic markets are pharmaceutical companies targeting to partner with academic research institutions?- What proprietary platforms and enabling technologies are these pharmaceutical companies trying to access?

Key Findings

With the patent cliff and high RD costs eroding corporate profitability, pharmaceutical companies will look for ways to replenish their pipelines by reaching out to academia in search of novel drug platforms- Despite the FDA approving 39 new drugs in 2012, the innovation gap continues, as many of these medicines are ‘me-too’ drugs, or orphan drugs indicated to treat small segments of the population suffering from rare diseases- Difficulty accessing capital and the continued economic recession have led to a deal adverse environment resulting in deals to decline on a global basis- Oncology, CNS, immunology and infectious diseases still remain hot therapeutic areas to strike licensing deals with academia

Scope

Full examination of 25 significant technology transfer deals from 2012 and 2013 involving large pharmaceutical companies and academic organizations including licensing structure and terms- Analysis of the key drivers, trends, and strategies behind the deals undertaken by these pharmaceutical companies across major therapeutic areas- Discussion of the unsustainability of the current drug research model and how Big Pharma’s embrace of collaboration and an open ecosystem could drive the next wave of scientific discovery- Tech Transfer in Action : Each section of the report includes a number of case studies and to highlight major themes within technology transfer- Platform assessment on enabling drug technologies being employed by academic research institutions of interest to pharmaceutical companies- Breakdown of disruptive innovation trends, including open-source patient data, pre-competitive information sharing, ‘Big Data’ and drug recycling/repurposing approaches

Key Benefits

Analyze and track the strategies that these pharmaceutical companies are using to gain share in an increasingly competitive marketplace- Target academic institutions with novel and proprietary technologies to maximize opportunities for strategic investment or partnerships- Formulate effective licensing strategies by understanding the various factors and deal terms considered when structuring tech-transfer partnerships- Use information as an independent source for your due diligence and transaction strategies

1 Table of Contents1 Table of Contents 41.1 List of Tables 91.2 List of Figures 102 Introduction 112.1 Catalyst 112.2 Related Reports 122.3 About PharmaSphere Report Series 133 A Changing and Challenging Deal Making Landscape 143.1 Overview 143.2 Deal Drivers 153.2.1 The Patent Cliff 153.2.2 Deal-Adverse Environment 183.2.3 Spike in Regulatory Approvals but Innovation Gap Continues 223.2.4 FDA’s Proposal to Lower Regulatory Standards in Early-Stage Alzheimer’s Research 233.2.5 More Stringent Regulatory Regime in a Post-Vioxx and Avandia World 243.2.6 Viewpoint: Vioxx and Avandia Cases 254 An Unsustainable RD Paradigm 274.1 Big Pharma’s Embrace of Disruptive Innovation May Fix Broken RD Model 284.1.1 Pre-Competitive Information Sharing 284.1.2 Open-Source Patient Data 294.1.3 ‘Big Data’ and Drug Discovery 304.1.4 Tech Transfer in Action: Astellas Pharma Taps IT for Drug Discovery 314.1.5 Drug Recycling 314.1.6 Viewpoint: Drug Repurposing at NCATS 324.1.7 Tech Transfer in Action: Roche Broad Join to Bring Failed Drugs Back from the Dead 335 Major Global Technology Transfer Alliances 345.1 The Bayh-Dole Act of 1980 345.2 Deals Overview 365.3 Biscayne Pharma Enters into Licensing Agreement with University of Miami for Growth Hormone-Releasing Technology 405.3.1 Deal Summary 405.3.2 Deal Analysis 405.4 Genoa Pharma Enters into Research Agreement with McMaster University for IPF 425.4.1 Deal Summary 425.4.2 Deal Analysis 425.5 AstraZeneca Partners with Vanderbilt University for Neuroscience Drug Discovery 445.5.1 Deal Summary 445.5.2 Deal Analysis 445.6 Trovagene Grants License for NPM1 Marker for AML to Duke University 455.6.1 Deal Summary 455.6.2 Deal Analysis 455.7 Synthetic Biologics and University of Texas Ink Research Deal to Fight Pertussis 475.7.1 Deal Summary 475.7.2 Deal Analysis 475.8 BMS and Vanderbilt University Sign Deal to Develop Drugs for Parkinson’s 495.8.1 Deal Summary 495.8.2 Deal Analysis 495.9 AstraZeneca and Broad Institute Partner to Advance Discovery of Antibacterial and Antiviral Agents 505.9.1 Deal Summary 505.9.2 Deal Analysis 505.10 Bayer HealthCare Opens New Lab Space – The CoLaborator – for Biotech Startups 515.10.1 Deal Summary 515.10.2 Deal Analysis 515.11 Novartis Enters into Licensing Agreement with Penn for CART-19 535.11.1 Deal Summary 535.11.2 Deal Analysis 535.12 Sanofi and BWH Agree to Develop Antibodies for Type 1 Diabetes 555.12.1 Deal Summary 555.12.2 Deal Analysis 555.13 AstraZeneca and Leading Academic Organizations Collaborate on Alzheimer’s Research 565.13.1 Deal Summary 565.13.2 Deal Analysis 565.14 Novo Nordisk Enters into RD Agreement with JDRF for Type 1 Diabetes 575.14.1 Deal Summary 575.14.2 Deal Analysis 575.15 Large Pharmas Unite with the Genome Institute of Singapore to Combat Cancer in Asian Populations 585.15.1 Deal Summary 585.15.2 Deal Analysis 585.15.3 Tech Transfer in Action: National University Singapore Startup AyoxxA Biosystems 595.16 University of Washington and ‘Big Pharma’ Join Forces to Research Drug Transporters 605.16.1 Deal Summary 605.16.2 Deal Analysis 605.17 Pharma and the University of Dundee Create Consortium on Cell Signaling Research 615.17.1 Deal Summary 615.17.2 Deal Analysis 615.18 Novo Nordisk and Oxford Join to Identify Novel Biomarkers for Rheumatoid Arthritis 625.18.1 Deal Summary 625.18.2 Deal Analysis 625.19 Elan Corporation and University of Cambridge Enter into Joint Venture to Discover New Therapies Targeting Neurodegenerative Disorders 635.19.1 Deal Summary 635.19.2 Deal Analysis 635.20 GSK and Yale Partner to Develop New Drugs Targeting Disease-Causing Proteins 645.20.1 Deal Summary 645.20.2 Deal Analysis 645.21 Big Pharma Companies and Research Institutions Tackle Early-Stage Research TB 655.21.1 Deal Summary 655.21.2 Deal Analysis 655.22 Accuray Signs Collaboration Agreement with University of Heidelberg to Provide Cutting-edge Research in Radiation Oncology 665.22.1 Deal Summary 665.22.2 Deal Analysis 665.23 UCB and Oxford University Join to Focus on Developing Innovative Medicines for Immunological and Neurological Disorders 675.23.1 Deal Summary 675.23.2 Deal Analysis 675.24 Large Pharma and King’s College London Establish a Center to Tackle Autism 695.24.1 Deal Summary 695.24.2 Deal Analysis 695.25 Merck Establishes an Independent Non-profit Drug Research Institute – the California Institute for Biomedical Research 705.25.1 Deal Summary 705.25.2 Deal Analysis 705.26 JJ and University of Queensland Develop Drugs Using Spider Venom for Treating Pain 715.26.1 Deal Summary 715.26.2 Deal Analysis 715.27 Sanofi and UCSF Form a Pact to Work on New Treatments for Diabetes 735.27.1 Deal Summary 735.27.2 Deal Analysis 735.27.3 Tech Transfer in Action: Tufts University Spin-off Anchor Therapeutics 746 Future Outlook 767 Appendix 777.1 Research Methodology 777.1.1 Coverage 777.1.2 Secondary Research 777.1.3 Expert Panel Validation 787.2 About the Author 787.2.1 Analyst 787.3 Director, Healthcare Industry Dynamics 797.4 Global Head of Healthcare 797.5 About the Industry Dynamics Team 797.6 GlobalData 807.7 Contact Us 807.8 Disclosure Information 807.9 Disclaimer 80

List of Tables

Table 1: Recent and Upcoming US Patent Expirations with FY2011 and FY2012 Sales Data 16Table 2: Deals Summary of Major Technology Transfer Alliances, January 2012-January 2013 38Table 3: Biscayne Pharma University of Miami, Deal Summary, 2013 40Table 4: Genoa Pharma McMaster University, Deal Summary, 2013 42Table 5: AstraZeneca Vanderbilt University, Deal Summary, 2013 44Table 6: Trovagene Duke University, Deal Summary, 2012 45Table 7: Synthetic Biologics University of Texas, Deal Summary, 2012 47Table 8: BMS Vanderbilt University, Deal Summary, 2012 49Table 9: AstraZeneca Broad Institute, Deal Summary, 2012 50Table 10: Bayer HealthCare Aronora, ProLynx, Deals Summary 2012 51Table 11: Novartis University of Pennsylvania, Deal Summary 2012 53Table 12: Sanofi Brigham and Women’s Hospital, Deal Summary 2012 55Table 13: AstraZeneca Leading Academic Organizations, Deal Summary 2012 56Table 14: Novo Nordisk JDRF, Deal Summary 2012 57Table 15: Eli Lilly, Merck, Pfizer Genome Institute of Singapore, Deal Summary 2012 58Table 16: AZ, Genentech, Merck University of Washington in St. Louis, Deal Summary 2012 60Table 17: Pharma University of Dundee, Deal Summary 2012 61Table 18: Novo Nordisk University of Oxford, Deal Summary 2012 62Table 19: Elan Corporation University of Cambridge, Deal Summary 2012 63Table 20: GSK Yale University, Deal Summary 2012 64Table 21: Pharma Texas AM University and Cornell Medical College, Deal Summary 2012 65Table 22: Accuray University of Heidelberg, Deal Summary 2012 66Table 23: UCB Oxford University, Deal Summary 2012 67Table 24: Eli Lilly, Janssen, Pfizer, Roche Kings College London, Deal Summary 2012 69Table 25: Merck, Pharma Biotech Start-ups, Deal Summary 2012 70Table 26: Johnson Johnson University of Queensland, Deal Summary 2012 71Table 27: Sanofi University of California at San Francisco, Deal Summary 2012 73

List of Figures

Figure 1: Lipitor Sales WW vs. US, 4Q11-4Q12 15Figure 2: Pharmaceuticals and Healthcare, Number of Deals and Deal Values (US $m), Globally from September 2012 – February 2013 18Figure 3: Pharmaceuticals Healthcare, Number of Deals by Region, February 2013 19Figure 4: Pharmaceuticals Healthcare, Number of Deals by Therapy Area, February 2013 20Figure 5: FDA Drug Approvals, 1995-2012 22Figure 6: Academic Technology Transfer Deals and Deal Values (US $m), from 2007-2012 36

To order this report:Drug_and_Medication Industry: PharmaSphere: Early-Stage Technology Transfer Collaborations – Enabling Platform Technologies Deal Synergies between Academia and the Pharmaceutical Industry

__________________________Contact Clare: clare@reportlinker.com US:(339) 368 6001Intl:+1 339 368 6001

SOURCE Reportlinker

http://rt.prnewswire.com/rt.gif?NewsItemId=BR13756Transmission_Id=201305141513PR_NEWS_USPR_____BR13756DateId=20130514

Copyright (C) 2013 PR Newswire. All rights reserved

PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling ...